EUVIMEDEUVIMED entdecken
Open Access

Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review

Aditya K Gupta, Mesbah Talukder, Avner Shemer, Bianca Maria Piraccini, Antonella Tosti

Skin Appendage Disorders · 2023 · 9 (6) · 423-437

DOI: 10.1159/000531890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Skin Appendage Disorders, online erschienen am 27.09.2023. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, ON, Canada. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Low-dose oral minoxidil (LDOM) has demonstrated a promising safety and efficacy profile in the treatment of various hair disorders, including male androgenetic alopecia (AGA) and female-pattern hair loss (FPHL); however, it lacks FDA approval. The usual LDOM starting dose for male AGA is 1–5 mg/day, depending on physician preference and the patient’s condition. For FPHL, it is 0.5–1 mg/day. The maximum dose is generally 5 mg/day. If patients respond well without major side effects, the dose may be gradually increased since the LDOM’s efficacy appears to be dose-dependent. Patients may use LDOM long term if the treatment outcome is satisfactory. The common side effects of LDOM are hypertrichosis and cardiovascular symptoms. Females are more prone to hypertrichosis than males. The side effects of LDOM can be categorized as (a) dose-dependent type A side effects (hypertrichosis and cardiovascular symptoms) and (b) idiosyncratic type B side effects (pericardial effusion). Minoxidil acts via multiple pathways. Although minoxidil has a relatively short half-life of around 4 h, its hypotensive effect may last approximately 72 h. Effective treatments for alopecia are limited. Therefore, LDOM could be an important addition to the available therapies for managing some hair disorders, including AGA.

Schlagwörter

Stichwörter der Autor:innen

Androgenetic alopeciaFemale-pattern hair lossHair disordersMinoxidilOral administration

Autor:innen und Institutionen

  • Mediprobe Research Inc., London, ON, Canada.
  • Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • School of Pharmacy, BRAC University, Dhaka, Bangladesh.
  • Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.

Zitieren

APA

Gupta, A. K., Talukder, M., Shemer, A., Piraccini, B. M., & Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders, 9(6), 423-437. https://doi.org/10.1159/000531890

Vancouver

Gupta AK, Talukder M, Shemer A, Piraccini BM, Tosti A. Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 2023;9(6):423-437. doi:10.1159/000531890

BibTeX
@article{Gupta2023,
  author = {Gupta, Aditya K and Talukder, Mesbah and Shemer, Avner and Piraccini, Bianca Maria and Tosti, Antonella},
  title = {Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review},
  journal = {Skin Appendage Disorders},
  year = {2023},
  volume = {9},
  number = {6},
  pages = {423--437},
  doi = {10.1159/000531890}
}
Kostenlos starten →